Suspected osseous recurrence visualized on a ⁶⁸Ga- DOTATATE PET/CT scan during the follow-up of a patient with a resected pulmonary carcinoid tumour

• References

• 1 Buchmann I, Henze M, Engelbrecht S. et al. Comparison of ⁶⁸Ga-dotatoc pet and ¹¹¹In-dtpaoc (octreoscan) spect in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-1626.
• 2 Chong S, Lee KS, Kim BT. et al. Integrated PET/CT of pulmonary neuroendocrine tumors: Diagnostic and prognostic implications. AJR Am J Roentgenol 2007; 188: 1223-1231.
• 3 Daniels CE, Lowe VJ, Aubry MC. et al. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007; 131: 255-260.
• 4 Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg 2005; 53: 168-172.
• 5 Fink G, Krelbaum T, Yellin A. et al. Pulmonary carcinoid: Presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647-1651.
• 6 Gabriel M, Decristoforo C, Kendler D. et al. ⁶⁸Gadota- tyr3-octreotide pet in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
• 7 Granberg D, Sundin A, Janson ET. et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003; 59: 793-799.
• 8 Gustafsson BI, Kidd M, Chan A. et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113: 5-21.
• 9 Haug AR, Assmann G, Rist C. et al. Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using ⁶⁸Gadotatate PET/CT. Radiologe 2010; 50: 349-354.
• 10 Haug AR, Auernhammer CJ, Wangler B. et al. ⁶⁸Gadotatate PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349-1356.
• 11 Hauso O, Gustafsson BI, Kidd M. et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
• 12 Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.
• 13 Kayani I, Bomanji JB, Groves A. et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-dotatate (dota-dphe1,tyr3- octreotate) and ¹⁸F-FDG. Cancer 2008; 112: 2447-2455.
• 14 Kayani I, Conry BG, Groves AM. et al. A comparison of ⁶⁸Ga-dotatate and ¹⁸F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009; 50: 1927-1932.
• 15 Koukouraki S, Strauss LG, Georgoulias V. et al. Comparison of the pharmacokinetics of ⁶⁸Ga-dotatoc and [¹⁸F]FDG in patients with metastatic neuroendocrine tumours scheduled for ⁹⁰Y-dotatoc therapy. Eur J Nucl Med Mol Imaging 2006; 33: 1115-1122.
• 16 Krenning EP, Kwekkeboom DJ, Bakker WH. et al. Somatostatin receptor scintigraphy with [¹¹¹Indtpa- d-phe1]- and [¹²³I-tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
• 17 Phan AT, Oberg K, Choi J. et al. Nanets consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010; 39: 784-798.
• 18 Rege SD, Hoh CK, Glaspy JA. et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82-90.
• 19 Righi L, Volante M, Tavaglione V. et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: A clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 2010; 21: 548-555.
• 20 Srirajaskanthan R, Kayani I, Quigley AM. et al. The role of ⁶⁸Ga-dotatate PET in patients with neuroendocrine tumors and negative or equivocal findings on ¹¹¹In-dtpa-octreotide scintigraphy. J Nucl Med 2010; 51: 875-882.
• 21 Winter PF, Lapke J, Winek R. Subcutaneous cavernous hemangioma visualized on an indium-111-octreotide scan. J Nucl Med 1996; 37: 1516-1517.
• 22 Yellin A, Zwas ST, Rozenman J. et al. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J 2005; 7: 712-716.